March 10, 2026 4:38pm

Pulling on opposite ends of a portfolio, with the goal of keeping share pricing within a positive distance while being pulled into a negative direction

Beware: 2 key inflation readings are due this week. February’s update on the Consumer Price Index is due Wednesday, followed by January’s Personal Consumption Expenditures index on Friday. Neither report will account for the recent spike in oil prices, which “could shift the interest rate calculus for the Fed.

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt, barely fulfills the need of a PPM raise … https://www.regmedinvestors.com/articles/13812

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Tuesday: The Dow closed DOWN -34.29 points or -0.07%, the S&P closed DOWN -14.49 points or -0.21% while the Nasdaq closed UP +1.158 points or +0.01%

  • Theme of the session: choppy trading as oil prices pulled back and traders kept an eye on the Iran conflict

Tuesday’s (my) 40-company covered sector’s advance/decline line opened positive with 25 incliners, 11 decliners and 4 flats, ending with a positive close of 21 incliners, 16 decliners and 3 flats

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Existing home sales rose 1.7% from January to a seasonally adjusted annual rate of 4.09 M, according to National Association of Realtors. Sales improved in all parts of the country except the Northeast, which experienced a prolonged cold snap and a blizzard in February.
  • The average price per gallon of unleaded gas in the U.S. climbed to about $3.54 per gallon on Tuesday, according to AAA.

The CBOE Fear (VIX) index, Tuesday closed at 25.46, after Monday’s 25.54, after Friday’s 20.49, Thursday’s 23.64, Wednesday’s 21.15, and last Tuesday’s 23.72

Metrics: Tuesday …

  • The RUT was down -5.59 points or -0.22%,
  • The XLV was down -1.11 points or -0.72%,
  • The NBI was up +43.57 points or +0.74%;
  • The XBI was up +0.31points or +0.24%
  • The IWM was down -0.26 or -0.10%;
  • The IBB was up +0.98 points or +0.57%,
  • The VIX was down -0.04 points or -0.16% at to 25.46

 

Q1/26 – March – 2 positive and 4 negative closes

  • February – 1 holiday, 8 negative and 11 positive sessions
  • anuary – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

  • December – 1 holiday, 8 positive and 14 negative closes
  • November – 1 holiday, 8 positive and 11 negative closes
  • October -1 neutral, 11 positive and 12 negative closes

 

Tuesday Closing UP (10 of 21) 

  • Vertex (VRTX +$38.30 after Monday’s +$4.18),    
  • Capricor Therapeutics (CAPR +$2.77 after Monday’s +$2.73),
  • Dyne Therapeutics (DYN +$2.09 after Monday’s +$2.83),
  • AxoGen (AXGN +$1.41),
  • Voyager Therapeutics (VYGR +$0.89),
  • Entrada Therapeutics (TRDA +$0.50),
  • Wave Life Sciences (WVE +$0.46),
  • Mesoblast (MESO +$0.31 after Monday’s -$0.42),
  • Ionis Pharmaceuticals (IONS +$0.30 after Monday’s +$1.32),
  • uniQure NV (QURE +$0.27 after Monday’s+$3.72),

Flat (3)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN) – Ponzi Scheme?
  • Precigen (PGEN)

Tuesday’s Closing DOWN (10 of 16): 

  • BioNTech (BNTX -$18.27),
  • IQAI Holdings (IQV -$7.64 after Monday’s +$4.06),
  • CRISPR Therapeutics (CRSP -$5.98),
  • Beam Therapeutics (BEAM -$1.54),
  • Arrowhead Pharmaceuticals (ARWR -$1,47),
  • BioLife Solutions (BLFS -$1.23),
  • Alnylam Pharmaceuticals (ALNY -$1.21 after Monday’s +$2.93),
  • Moderna (MRNA -$0.76 after Monday’s +$3.22),
  • Vericel (VCEL -$0.72),
  • Supernus Therapeutics (SUPN -$0.50)

 

The Bottom Line: More of the … WHY

US stocks ended little changed on Tuesday to cap a volatile trading session as investors weighed President Trump's hint at a swift end to the Iran war, while oil futures trimmed losses.

Although, volume was considerably lower on the Nasdaq and on the NYSE versus Monday.

 

Some good:  Vertex Pharmaceuticals (VRTX) gapped up nearly 7% in heavy trading after announcing … positive test results for potential treatment for an autoimmune disease that affects the kidneys.

  • Shares revisited a buy zone of a flat base up to 511.90 after a breakout had faded and triggered the 7% sell rule. Shares reclaimed their 50-day line on the stock market today.
  • VRTX stock is on pace for its largest increase since December 2023, when it rose 13.23%, according to Dow Jones Market Data.

 

Looking at domestic economic reports, investors will be watching closely for Wednesday's Consumer Price Index and Friday's Personal Consumption Expenditures index readings, though neither will capture the effect of oil's dramatic recent surge on price pressures just yet. <Yahoo Finance>

 

Earnings release dates: soon to be catching up

  • Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)
  • Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)
  • Thursday – 2/26 – Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)
  • Monday - 3/2 – Dyne Therapeutics (DYN)
  • Thursday – 3/5 – Regenxbio (RGNX), Compass therapeutics (CMPX)
  • Thursday – 3/12 – Capricor Therapeutics (CAPR)
  • Monday – 3/16 – Agenus (AGEN)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering rock the C&GT sector and markets!

  • As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

March – 2nd week

  • 3/10 - Tuesday closed positive with 21 incliners, 16 decliners and 3 flats
  • 3/9 - Monday closed positive with 35 incliners, 2 decliners and 3 flats

March – 1st week

  • 3/6 - Friday closed negative with 14 incliners, 24 decliners and 2 flats
  • 3/5 – Thursday closed negative with 7 incliners, 32 decliners and 1 flat
  • 3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats
  • 3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats
  • 3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Tuesday: Vertex (VRTX), Capricor Therapeutics (CAPR) and Dyne Therapeutics (DYN)
  • Monday: Vertex (VRTX), IQIA Holdings (IQV) and UniQure NV (QURE)
  • Friday: UniQure NV (QURE), Capricor Therapeutics (CAPR) and Solid Biosciences (SLDB)

The worst three (3) in the session: Losers

  • Tuesday: BioNTech (BNTX), CRISPR Therapeutics (CRSP) and IQIA Holdings (IQV)
  • Monday: Mesoblast (MESO) and Compass Therapeutics (CMPX)
  • Friday: Vertex (VRTX), IQIA Holdings (IQV) and Arrowhead Pharmaceuticals (ARWR)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.